While the mortality rate of BC patients has steadily declined over the years owing to earlier detection and better targeted therapies, triple negative BC tumors (TNBC, tumors which lack hormone receptors and HER2 amplification) still have a poor prognosis due to their higher tendency to relapse [3]. The gene discussed is ERBB2; the disease is breast cancer.